Theravance Biopharma, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Theravance Biopharma, Inc. (TBPH) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- Theravance Biopharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.08M, a 14.47% increase year-over-year.
- Theravance Biopharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.06M, a 9.32% increase year-over-year.
- Theravance Biopharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.11M, a 5.13% increase year-over-year.
- Theravance Biopharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.00M, a 11.25% decline year-over-year.
- Theravance Biopharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $4.01M, a 9.04% decline from fiscal 2024.
- Theravance Biopharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $4.41M, a 6.31% increase from fiscal 2023.
- Theravance Biopharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $4.15M, a 4.09% increase from fiscal 2022.
- Theravance Biopharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $3.99M, a 5.36% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.13M 10-Q · filed 2026-08-11 | $3.24M derived: sum of 3 quarters · filed 2026-08-11 | $4.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-07 | $2.16M derived: sum of 2 quarters · filed 2026-05-07 | $3.17M derived: sum of 3 quarters · filed 2026-05-07 | $4.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.11M derived: sum of 2 quarters · filed 2026-03-23 | $3.05M derived: sum of 3 quarters · filed 2026-08-11 | $4.01M 10-K · filed 2026-03-23 |
| 2025-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.94M derived: sum of 2 quarters · filed 2026-08-11 | $2.91M 10-Q · filed 2025-11-12 | $3.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $940.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.91M 10-Q · filed 2026-08-11 | $2.96M derived: sum of 3 quarters · filed 2026-08-11 | $4.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $966.00K 10-Q · filed 2026-05-07 | $2.02M derived: sum of 2 quarters · filed 2026-05-07 | $3.15M derived: sum of 3 quarters · filed 2026-05-07 | $4.28M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.18M derived: sum of 2 quarters · filed 2026-03-23 | $3.31M derived: sum of 3 quarters · filed 2026-03-23 | $4.41M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.26M derived: sum of 2 quarters · filed 2025-11-12 | $3.36M 10-Q · filed 2025-11-12 | $4.79M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.23M 10-Q · filed 2025-08-13 | $3.66M derived: sum of 3 quarters · filed 2025-08-13 | $4.57M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.10M 10-Q · filed 2025-05-12 | $2.53M derived: sum of 2 quarters · filed 2025-05-12 | $3.44M derived: sum of 3 quarters · filed 2025-05-12 | $4.22M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $2.33M derived: sum of 2 quarters · filed 2025-03-07 | $3.12M derived: sum of 3 quarters · filed 2025-03-07 | $4.15M 10-K · filed 2025-03-07 |
| 2023-09-30 | $907.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.69M derived: sum of 2 quarters · filed 2024-11-14 | $2.72M 10-Q · filed 2024-11-14 | $4.43M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $786.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.82M 10-Q · filed 2024-08-08 | $3.52M derived: sum of 3 quarters · filed 2024-08-08 | $4.49M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-15 | $2.74M derived: sum of 2 quarters · filed 2024-05-15 | $3.71M derived: sum of 3 quarters · filed 2024-05-15 | $4.68M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.67M derived: sum of 2 quarters · filed 2024-03-01 | $3.65M derived: sum of 3 quarters · filed 2024-03-01 | $3.99M 10-K · filed 2024-03-01 |
| 2022-09-30 | $970.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.94M derived: sum of 2 quarters · filed 2023-11-09 | $2.28M 10-Q · filed 2023-11-09 | $3.31M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $973.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.31M 10-Q · filed 2023-08-09 | $2.34M derived: sum of 3 quarters · filed 2023-08-09 | $3.35M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $341.00K 10-Q · filed 2023-05-10 | $1.37M derived: sum of 2 quarters · filed 2023-05-10 | $2.38M derived: sum of 3 quarters · filed 2023-05-10 | |
| 2021-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.03M derived: sum of 2 quarters · filed 2023-03-01 | $3.79M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.76M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $1.75M 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $3.34M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |